Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $124.30, marking a -1.03% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 1.65%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 3.07%.

Shares of the HIV and hepatitis C drugmaker witnessed a loss of 3.08% over the previous month, trailing the performance of the Medical sector with its gain of 3.59%, and the S&P 500's gain of 0.48%.

The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company's upcoming EPS is projected at -$5.31, signifying a 364.18% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.36 billion, up 3.98% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.79 per share and revenue of $30.37 billion, which would represent changes of -109.69% and +3.16%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Gilead Sciences. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 1.73% fall in the Zacks Consensus EPS estimate. Gilead Sciences presently features a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 147, finds itself in the bottom 40% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research